Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:16 AM ET Form 4
Insider Buying Exagen Inc. XGN

Exagen Insider Jorey Chernett Buys $373K of Stock

Jorey Chernett bought 71,315 shares of Exagen Inc. at $5.23 a share, worth $373K in total on Nov 11, 2026. Shares held after the trade: 2,696,940 (+2.7%).

Value
$373K
Shares
71,315
Price
$5.23
Holding change
+2.7%
Trade date
Nov 11, 2026
8:16 AM ET 8-K
M&A Deal Trustmark Corp TRMK

Trustmark Signs $3.2B M&A Deal with Hancock Whitney Corporation

Trustmark Corporation has entered into a definitive agreement to merge with and into Hancock Whitney Corporation in an all-stock transaction valued at approximately $3.2 billion. The merger will create a premier Gulf South regional bank with approximately $58 billion in assets and is expected to close in the first quarter of 2027.

Value
$3.2B
Counterparty
Hancock Whitney Corporation
8:15 AM ET 8-K
Financial Results SES AI Corp SES

SES AI Financial Results

SES AI Corp reported its Q3 2026 financial results, highlighting a 31% sequential revenue increase to $6.6 million and a narrowing GAAP net loss of $13.4 million. The company successfully ramped its Chungju production line to 1 million cells per year and introduced its 'Flywheel' strategy focusing on drones, energy storage, and material discovery.

Term
3 years
8:15 AM ET 8-K
Product Launch Data443 Risk Mitigation, Inc. ATDS

Data443 Risk Mitigation Product Launch

Data443 Risk Mitigation announced the commercial launch of its Convaa.ai™ enterprise AI collaboration platform on the Apple App Store. The application is specifically optimized for the iPhone Duo foldable smartphone, allowing multi-person live AI collaboration sessions on the device's 7.6-inch inner display.

8:14 AM ET 8-K
Financial Results Suburban Propane Partners LP SPH

Suburban Propane Partners Financial Results

Suburban Propane Partners reported fiscal year 2026 net income of $109.0 million and Adjusted EBITDA of $284.0 million, a 2.2% increase over the prior year. The company highlighted strong heat-related demand in its propane segment and a 13% increase in average daily renewable natural gas (RNG) injections following facility upgrades and new capacity in New York.

Term
FY2026

“Fiscal 2026 was another strong year for Suburban Propane with solid results in our propane operations, the completion of capital projects to increase the scale of our renewable natural gas (“RNG”) business, and continued debt reduction to further strengthen our financial position.”

Michael A. Stivala, President and Chief Executive Officer

“With these investments in place, we enter fiscal 2027 with a larger, more reliable RNG platform, opportunities to increase production through capacity optimization and higher feedstock intake, and the ability to enhance our earnings profile from the recognition of additional PTCs.”

Michael A. Stivala, President and Chief Executive Officer
8:14 AM ET 8-K
Investor Presentation Dixie Group Inc DXYN

Dixie Group Investor Presentation

The Dixie Group, Inc. furnished an updated investor presentation for November 2026, superseding its previous presentation from August 2026. The materials provide a strategic overview of the company's history, its focus on the upper-end residential flooring market, and historical net sales data through 2025.

8:14 AM ET 10-Q
Financial Results MeiraGTx Holdings plc MGTX

MeiraGTx Holdings Q3 2026 Results: Net Loss of $51.2M, Loss Widens

MeiraGTx reported a significant increase in total revenue to $326.5 million for the nine months ended September 30, 2026, primarily driven by license and service revenue from related parties. This resulted in a net income of $63.1 million for the period, compared to a net loss of $129.3 million in the prior year, despite a net loss in the third quarter of 2026.

Key figure
Net loss $51.2M
8:13 AM ET 8-K
Financial Results Dixie Group Inc DXYN

Dixie Group Financial Results

The Dixie Group reported its third consecutive profitable quarter, with net sales increasing 4.6% to $65.2 million and net income of $577,000 compared to a significant loss in the prior year. The company attributed the improvement to cost reductions and operating efficiencies despite industry headwinds from high interest rates and inflation.

Term
Q3 2026

“We are pleased to report our third consecutive profitable quarter of 2026. Net sales increased 4.6% over the third quarter of last year, and we returned to operating income for the quarter compared to an operating loss in the prior year period. Gross profit margins improved to 26.6% from 24.8%, reflecting cost reductions and improved operating efficiencies in our operations.”

Daniel K. Frierson, Chairman and Chief Executive Officer
8:13 AM ET 8-K
Financial Results Forum Markets Inc FRMM

Forum Markets Financial Results

Forum Markets reported Q3 2026 revenue of $2.0 million and net income of $7.9 million, which included a $13.9 million non-cash gain from digital asset fair value changes. The company highlighted the formation of its Forum Edge AI joint venture and the acquisition of two additional commercial aircraft engines during the quarter.

Term
Q3 2026

“Over the past three months, we established our AI infrastructure platform through our Forum Edge AI joint venture and made it the primary focus of our capital and our growth. We have established the foundation for what we believe can become a substantial AI infrastructure business.”

McAndrew Rudisill, chairman and chief executive officer of Forum Markets

“The midterm elections significantly disrupted an already tightening AI compute market, accelerating rising costs for equipment, compute and financing. These conditions increase the value of data center capacity that is already permitted, powered and built, which is exactly what Forum has.”

McAndrew Rudisill, chairman and chief executive officer of Forum Markets
8:11 AM ET 10-Q
Financial Results Lucid Diagnostics Inc. LUCD

Lucid Diagnostics Q3 2026 Results: Net Loss of $6.68M, Loss Narrows

Lucid Diagnostics reported a net loss of $6.7 million for the quarter ended September 30, 2026, an improvement from the $10.4 million loss in the prior year period. Total revenue remained flat year-over-year at $1.2 million, while the company significantly reduced its total liabilities from $29.5 million at year-end 2025 to $21.9 million.

Key figure
Net loss $6.68M
8:11 AM ET 8-K
Financial Results Theriva Biologics, Inc. TOVX

Theriva Biologics Financial Results

Theriva Biologics reported third quarter 2026 financial results, highlighting a cash position of $8.5 million and a runway into Q1 2027. The company also noted the completion of the sale of its SYN-004 portfolio to Biossil Labs for $350,000 upfront and up to $91 million in milestones.

“We are pleased with the clinical progress achieved this quarter. Patient enrollment and dosing in the VIRAGE2 trial is progressing well, and we anticipate completing enrollment by the end of the fourth quarter of this year.”

Steven A. Shallcross, Chief Executive Officer of Theriva Biologics

“The recently signed asset sale agreement for SYN-004 (ribaxamase) and the related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. demonstrates our commitment to deriving value from our legacy microbiome programs while continuing to focus on the development of our lead program VCN-01.”

Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
8:10 AM ET 8-K
M&A Deal Silence Therapeutics plc SLN

Silence Therapeutics M&A Deal with Merck KGaA

Silence Therapeutics announced it has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions and shareholder approval. While the filing also contains Q3 2026 financial results, the pending acquisition is the primary material event for investors.

Counterparty
Merck KGaA
8:10 AM ET 8-K
M&A Deal Inflection Point Acquisition Corp. VII IPXG

Inflection Point Acquisition Corp. VII M&A Deal with Elroy Air, Inc.

Inflection Point Acquisition Corp. VII entered into a second amendment to its business combination agreement with Elroy Air, Inc. The amendment simplifies the stock exchange process by eliminating the requirement for letters of transmittal and updates the closing conditions regarding seller lock-up agreements for certain equity holders and employees.

Counterparty
Elroy Air, Inc.
8:10 AM ET 8-K
Financial Results enCore Energy Corp. EU

enCore Energy Financial Results

enCore Energy reported Q3 2026 revenue of $16.7 million, an 88% increase year-over-year driven by higher uranium delivery volumes and stronger realized prices. The company reported a net loss of $33.9 million for the quarter as it focused on wellfield development at Alta Mesa and Upper Spring Creek while implementing cost-reduction measures.

Term
Q3 2026

“2026 has been a challenging year for enCore, and we have responded by reducing costs and focusing our capital where it matters most. We optimized operations to align spending with permitting timelines, while continuing to build the wellfields and infrastructure that underpin our next phase of extraction.”

Rich Little, Chief Executive Officer
8:09 AM ET 8-K
Shareholder Meeting Health In Tech, Inc. HIT

Health In Tech Shareholder Meeting

Health In Tech held its 2026 Annual Meeting of Stockholders where shareholders elected five directors and approved an amendment to increase authorized capital stock from 220 million to 720 million shares. Additionally, stockholders approved the potential issuance of Class A Common Stock under a Standby Equity Purchase Agreement and an amendment to the 2024 Equity Incentive Plan to increase authorized shares to 30.7 million.

8:09 AM ET 10-Q
Financial Results Aktis Oncology, Inc. AKTS

Aktis Oncology Q3 2026 Results: Net Loss of $29.9M, Loss Widens

Aktis Oncology reported a net loss of $72.4 million for the nine months ended September 30, 2026, compared to $48.6 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet during the period through an initial public offering and the conversion of preferred stock, ending the quarter with $492.9 million in cash and marketable securities.

Key figure
Net loss $29.9M
8:09 AM ET 8-K
Leadership Change Hubspot Inc HUBS

Hubspot Leadership Change

HubSpot announced that Yamini Rangan has stepped down as CEO and board member, with co-founder Brian Halligan returning as President and CEO effective November 12, 2026. Additionally, CFO Kate Bueker will retire in February 2027 and be succeeded by Karen Burgess, formerly of Adobe. The company framed the leadership transition as a 'refounding' to focus on AI-driven customer relationship tools.

8:08 AM ET 8-K
Financial Results Avalyn Pharma Inc. AVLN

Avalyn Pharma Financial Results

Avalyn Pharma reported financial results for the third quarter of 2026, ending the period with $386.6 million in cash and a runway projected into 2029. The company highlighted clinical progress, including the initiation of a Phase 1 study for its AP03 combination therapy and upcoming Phase 2 data readouts for AP01 and AP02 expected in 2027.

Term
Q3 2026

“As we approach year end, I’m proud of the progress we’ve made across our portfolio and the strong foundation we’ve built for what we expect to be a transformational 2027, with data anticipated across all three of our programs.”

Lyn Baranowski, Chief Executive Officer of Avalyn

“We remain confident in the potential of inhaled therapies to transform the standard of care for pulmonary fibrosis by delivering effective, well-tolerated treatments both as monotherapies and in combination.”

Lyn Baranowski, Chief Executive Officer of Avalyn
8:08 AM ET 8-K
Financial Results MeiraGTx Holdings plc MGTX

MeiraGTx Holdings Financial Results

MeiraGTx reported third quarter 2026 financial results and provided a regulatory update for its lead candidate bota-vec, with an MAA submission to the EMA expected in December 2026 and a BLA submission to the FDA in Q1 2027. The company is preparing for a potential commercial launch of bota-vec for XLRP in late 2027 while advancing its Phase 2 AQUAx2 study for radiation-induced xerostomia.

“We are pleased to report that we have now completed much of the work towards submission of full global regulatory filings with the EMA and FDA for bota-vec for the treatment of XLRP. The MAA dossier is complete and awaiting submission and the BLA is expected to follow early next year.”

Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx

“We are actively preparing for our pivotal Phase 2 AQUAx2 12-month data readout for the treatment of radiation-induced xerostomia in mid-2027. As we progress these two lead programs through filing for potential approval and commercialization, we are also advancing several programs towards IND.”

Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx
8:08 AM ET 8-K
Leadership Change Profound Medical Corp. PROF

Profound Medical Leadership Change

Profound Medical Corp. announced a leadership transition where Richard R. Fabian will succeed Arun Menawat as President and CEO effective January 15, 2027, with Dr. Menawat becoming Executive Chairman. Additionally, Jason Mills was appointed to the Board of Directors following the resignation of Cynthia Lavoie.

8:07 AM ET 10-Q
Financial Results Liqtech International Inc LIQT

Liqtech International Q3 2026 Results: Net Loss of $1.84M, Loss Widens

LiqTech International reported revenue of $12.9 million for the nine months ended September 30, 2026, a slight decrease from $13.4 million in the prior year period. The company significantly strengthened its balance sheet, increasing cash to $13.9 million and total stockholders' equity to $24.3 million, primarily through the issuance of common stock and the settlement of notes payable.

Key figure
Net loss $1.84M
8:06 AM ET 10-Q
Financial Results Creatd, Inc. CRTD

Creatd Q3 2026 Results: Net Loss of $2.77M, Loss Widens

Creatd, Inc. reported a significant increase in net loss for the nine months ended September 30, 2026, reaching $20.2 million compared to $5.1 million in the prior year, primarily driven by a surge in stock-based compensation and general administrative expenses. Net revenue declined by approximately 27% year-over-year to $603,722, while the company's total stockholders' equity decreased to $7.97 million.

Key figure
Net loss $2.77M
8:06 AM ET 8-K
Capital Raise Prime Medicine, Inc. PRME

Prime Medicine Capital Raise of $144M

Prime Medicine, Inc. entered into an underwriting agreement for a public offering of 35,714,286 shares of common stock at $3.50 per share. The company also granted underwriters a 30-day option to purchase up to an additional 5,357,142 shares, bringing the total potential gross proceeds to approximately $143.75 million. Proceeds will be used to advance the company's Wilson disease and alpha-1 antitrypsin deficiency programs and for general corporate purposes.

Value
$144M
Counterparty
Jefferies LLC
8:05 AM ET 8-K
Deal Termination Western Union CO WU

Western Union Deal Termination with International Money Express, Inc.

Western Union terminated its definitive merger agreement to acquire International Money Express (Intermex) after failing to reach acceptable terms with California's Department of Financial Protection and Innovation (DFPI). The regulator imposed conditions that would have required material changes to Western Union's business model and agent relationships, which the company deemed not in the best interests of shareholders. No termination fee is payable by either party, though Intermex has reportedly threatened legal action regarding the termination.

Counterparty
International Money Express, Inc.
8:05 AM ET 8-K
Financial Results Lucid Diagnostics Inc. LUCD

Lucid Diagnostics Financial Results

Lucid Diagnostics reported third quarter 2026 financial results, highlighting the commencement of Medicare reimbursement for its EsoGuard Esophageal DNA Test at a rate of $1,938.01 per test. The company performed 2,871 tests during the quarter and reported record monthly test volume in October following the Medicare coverage milestone.

“Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test. This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”

Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer

“Our pursuit of EsoGuard’s enormous clinical and commercial opportunity is now substantially less constrained by external factors. Lucid’s near-term growth now depends almost entirely on our team’s commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint.”

Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer
8:05 AM ET 8-K
Financial Results Aktis Oncology, Inc. AKTS

Aktis Oncology Financial Results

Aktis Oncology reported financial results for the third quarter of 2026, highlighting the initiation of its third Phase 1b clinical trial (BActinium-2) for AKY-2519. The company also operationalized its in-house GMP manufacturing facility in Boston and remains on track to present preliminary clinical data for its lead programs in 2027.

Term
Q3 2026

“Aktis is on a trajectory to redefine radiopharmaceuticals as a major pillar of cancer treatment by expanding the modality to more targets, broader indications, and larger patient populations. In the third quarter, we continued to make tremendous progress operationalizing this vision.”

Matthew Roden, Ph.D., President and Chief Executive Officer

“With the initiation of the BActinium-2 trial of AKY-2519, we now have three clinical trials underway in the U.S. across two novel targets, Nectin-4 and B7-H3, which are both implicated in a range of solid tumor types. We also opened the first backfill cohorts in our ongoing NECTINIUM-2 and BActinium-1 trials to further characterize safety and preliminary antitumor activity at the selected doses, while dose escalation continues in both studies.”

Matthew Roden, Ph.D., President and Chief Executive Officer
8:05 AM ET 10-Q
Financial Results Kyverna Therapeutics, Inc. KYTX

Kyverna Therapeutics Q3 2026 Results: Net Loss of $41.9M, Loss Widens

Kyverna Therapeutics reported a net loss of $119.99 million for the nine months ended September 30, 2026, compared to $123.50 million in the prior year period. The company's cash and marketable securities position decreased to $170.57 million as of September 30, 2026, down from $279.25 million at the end of 2025, primarily due to ongoing research and development expenses.

Key figure
Net loss $41.9M
8:04 AM ET Form 4
Insider Selling Scotts Miracle-Gro Co SMG

Scotts Miracle-Gro Insider David C. Evans Sells $176K of Stock

David C. Evans sold 2,655 shares of Scotts Miracle-Gro Co at $66.42 a share, worth $176K in total on Nov 9, 2026. Shares held after the trade: 25,405 (-9.5%).

Value
$176K
Shares
2,655
Price
$66.42
Holding change
-9.5%
Trade date
Nov 9, 2026
8:04 AM ET 8-K
Financial Results Cohen & Co Inc. COHN

Cohen & Co Financial Results

Cohen & Co Inc. reported third quarter 2026 financial results, generating $32.4 million in total revenue and $6.9 million in enterprise net income. The company's capital markets division underwrote six SPAC IPOs during the quarter, though results were impacted by $17 million in mark-to-market adjustments. Additionally, the board declared a quarterly dividend of $0.25 per share and appointed Daniel G. Cohen as CEO.

Term
3 years

“We are encouraged by the continued strong performance in our full-service boutique investment bank, Cohen & Company Capital Markets (“CCM”), and in our gestation repo business. During the third quarter, CCM underwrote six SPAC IPOs and one closed-end fund, raising $1.8 billion for clients, and advised on and raised capital for eight de-SPAC transactions, exemplifying its status as a leading SPAC advisor on Wall Street.”

Daniel G. Cohen, Executive Chairman and Chief Executive Officer

“While third quarter results were unfavorably impacted by more than $17 million of mark-to-market adjustments in our investment banking and new issue revenue line, in large part due to the environment in our businesses, we still generated $6.9 million of enterprise net income and $648,000 of adjusted pre-tax income.”

Daniel G. Cohen, Executive Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.